Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Mahmudul Khan"'
Autor:
Alan Anderson, Fuad El Rassi, Michael R. Debaun, Modupe Idowu, Julie Kanter, Soheir Adam, Susanna Curtis, Darla Liles, Biree Andemariam, Morgan L. Mclemore, Robert Sheppard Nickel, Poornima Ramadas, Jincy Paulose, Dram Laine, Mahmudul Khan, Deepika Darbari, Arthur L. Burnett
Publikováno v:
HemaSphere, Vol 7, p e54376db (2023)
Externí odkaz:
https://doaj.org/article/ff2f5e5713de48b881a6ba3fd4d4c1f6
Autor:
Ehab Atallah, Michael Mauro, Koji Sasaki, Moshe Yair Levy, Paul Koller, Islam Sadek, Daisy Yang, Julie Ruckel-Kumar, Mahmudul Khan, Jorge Cortes
Publikováno v:
HemaSphere, Vol 7, p e8144284 (2023)
Externí odkaz:
https://doaj.org/article/b14fd948cbf643d5b02bfeb43eabea99
Autor:
Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, Andres Siulnik, Vikas Gupta, Mahmudul Khan, John F. DiPersio, Mari McQuitty, John V. Catalano, Deborah S. Hunter, Laurent Knoops, Michael Deininger, Francisco Cervantes, Carole Miller, Alessandro M. Vannucchi, Richard T. Silver, Tiziano Barbui, Moshe Talpaz, Giovanni Barosi, Elliott F. Winton, Estella Mendeson, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, William Sun, Victor Sandor, Hagop M. Kantarjian, Claire Harrison
Publikováno v:
Haematologica, Vol 99, Iss 2 (2014)
Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best avai
Externí odkaz:
https://doaj.org/article/23c64710c3624182a69371f30b69787f
Autor:
Koji Sasaki, Michael Mauro, Moshe Yair Levy, Ehab L. Atallah, Paul B. Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes
Publikováno v:
Blood. 140:6784-6786
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d73d1ee57a5ade8c70f4c5b62a750d2e
https://doi.org/10.1182/blood-2022-167044
https://doi.org/10.1182/blood-2022-167044
Autor:
Alan Anderson, Fuad El Rassi, Michael R. DeBaun, Modupe Idowu, Julie Kanter, Soheir Adam, Susanna Curtis, Darla Liles, Biree Andemariam, Morgan L. McLemore, Robert Sheppard Nickel, Poornima Ramadas, Jincy Paulose, Dramane I Laine, Mahmudul Khan, Deepika S. Darbari, Arthur L. Burnett
Publikováno v:
Blood. 140:1636-1638
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ffb99853585245a72c89f832e2056be
https://doi.org/10.1182/blood-2022-157004
https://doi.org/10.1182/blood-2022-157004
Autor:
Koji Sasaki, Michael J. Mauro, Moshe Y. Levy, Ehab L. Atallah, Paul Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa7345c4f3dd9f7022aac04125e11d39
https://doi.org/10.1016/s2152-2650(22)00907-7
https://doi.org/10.1016/s2152-2650(22)00907-7
Autor:
Koji Sasaki, Michael J. Mauro, Moshe Y. Levy, Ehab L. Atallah, Paul Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e881ba091465e1509f48bc9babaeda6c
https://doi.org/10.1016/s2152-2650(22)01386-6
https://doi.org/10.1016/s2152-2650(22)01386-6
Autor:
Martin Griesshammer, Srdan Verstovsek, Julian Perez Ronco, Jingjin Li, Mahmudul Khan, Brian Gadbaw, Hui-Ling Zhen, Francesco Passamonti, Simon Durrant, Paola Guglielmelli, Jean-Jacques Kiladjian, Tamás Masszi, Güray Saydam, Mark M. Jones
Publikováno v:
Annals of Hematology. 97:617-627
WOS: 000426644800007
PubMed ID: 29396713
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving po
PubMed ID: 29396713
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dadda0e32b9a832b13abe6c63c87f13
https://doi.org/10.1007/s00277-017-3225-1
https://doi.org/10.1007/s00277-017-3225-1
Autor:
Paola Guglielmelli, Carole B. Miller, Mark M. Jones, Francesco Passamonti, Dany Habr, Simon Durrant, Fabrizio Pane, Pierre Zachee, Deborah S. Hunter, Mahmudul Khan, Srdan Verstovsek, William Sun, Jingjin Li, Jean-Jacques Kiladjian, Tamás Masszi, Martin Griesshammer, Claire N. Harrison
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8c09071019779bb873a600db6ed2f1
http://hdl.handle.net/11588/721797
http://hdl.handle.net/11588/721797
Autor:
Francesca Palandri, Martin Griesshammer, Caroline Bensasson, Jeannie Callum, Julian Perez Ronco, Güray Saydam, Serdar Sivgin, Paola Guglielmelli, Timothy Devos, Francesco Passamonti, Miklos Egyed, Giulia Benevolo, Mahmudul Khan
Publikováno v:
Annals of Hematology
Web of Science
Web of Science
WOS: 000440976800009
PubMed ID: 29804268
RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients wi
PubMed ID: 29804268
RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd79cf5b93193c9a546a1995f501851a
http://hdl.handle.net/11383/2073878
http://hdl.handle.net/11383/2073878